AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comSEP 182 min read$BMY

Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?

Bristol Myers (BMY) reported positive two-year data from the POETYK PsA-2 study on Sotyktu, showing sustained efficacy and consistent safety. Sotyktu's PsA approval expands its market, with $156M revenue in H1 2026. BMY's growth portfolio includes Sotyktu, with competition from Amgen's Otezla and Takeda's zasocitinib. BMY shares up 16.5% YTD, trading at 9.58x forward earnings.

Original reporting
theglobeandmail.com
Published Sep 18, 2026, 8:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 11:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects? — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$BMYBullishMed
01

Why it matters

The two-year data validates Sotyktu's efficacy, potentially increasing its market share and supporting higher revenue forecasts.

02

Market read

Positive long-term trial results could lift BMY stock and influence the broader immunology sector.

03

What to watch

Future data from SLE and Sjögren's programs will be needed to sustain long-term growth.

Relevance 8/10Novelty 8/10Timing: today

Background

Bristol Myers' growth portfolio relies on expanding Sotyktu beyond psoriasis into psoriatic arthritis and other autoimmune diseases.

Company-level read

Ticker impact

$BMYBullishHigh confidence
Context

Bristol Myers announced positive two-year Phase III data for Sotyktu, showing sustained efficacy and safety in psoriatic arthritis.

Expected impact

Potential upside for BMY as investors price in expanded indication and revenue growth.

Evidence & confidence

New pivotal trial data for a recently approved drug typically drives share price appreciation, especially with $156M H1 revenue and pipeline expansion.

Market effects

Sector

Strengthens the TYK2 inhibitor segment and may pressure competitors like Amgen's Otezla.

Regional

U.S. and global immunology markets see renewed interest in oral TYK2 therapies.

Global

Adds confidence to biotech investors tracking long-term data releases.

Counterpoint

What could challenge this read

If safety concerns emerge in broader patient populations, the upside could be limited.

Key entities

  • Company
    Bristol Myers

    Pharmaceutical company reporting the data.

  • Drug
    Sotyktu (deucravacitinib)

    Oral TYK2 inhibitor under study for PsA.

Read at source← All news

Related articles

SEP 19
$BMYMedAI 8/10

Bristol Myers arlo-cel meets Phase 2 endpoints in heavily pretreated RRMM

Bristol Myers Squibb (BMY) reported positive Phase 2 results for its experimental cell therapy, arlo-cel, in heavily pretreated relapsed and refractory multiple myeloma. The trial met primary and key secondary endpoints, showing significant overall and complete response rates. The company also presented long-term data for Camzyos (mavacamten), showing sustained efficacy and safety in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients over five years. Shares of Bristol-Myers Squi

scanx.trade2 min
SEP 19
$BMYMedAI 9/10

Bristol Myers Squibb ends Cellares partnership over Breyanzi tech

Bristol Myers Squibb (BMY) received FDA accelerated approval for ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone for relapsed or refractory multiple myeloma. The approval is based on Phase 3 trial data showing improved MRD-negative complete response rates. ZENBEXUS carries boxed warnings for embryo-fetal toxicity and thromboembolism. Analysts forecast U.S. sales to exceed $1 billion annually by 2031. BMY shares were down 1.36% at $63.77 at the time of publication.

scanx.trade2 min
SEP 18
$BMYMed

BMS scraps Orum’s targeted degrader after reviewing Phase 1 data

Bristol Myers Squibb (BMS) has discontinued development of ORM-6151, a targeted degrader therapy acquired from Orum Therapeutics in 2023. According to Orum's regulatory filing, BMS reviewed Phase 1 data and decided to stop further development. The deal, worth $100 million upfront and up to $80 million in milestones, will not require Orum to return the initial payment. Orum still has $180 million in cash and plans to focus on its remaining pipeline and DAC platform.

biospace.com2 min
SEP 17
$BMYMedAI 9/10

Bristol Myers Squibb reports Sotyktu two-year trial results

Bristol Myers Squibb (BMY) reported two-year Phase 3 trial results for Sotyktu, showing sustained efficacy and no new safety signals in adults with psoriatic arthritis. ACR20/50/70 response rates were 76.2%, 52.6%, and 34.6% at Week 104 for continuous treatment. The company plans to present full results at upcoming medical conferences.

grafa.com2 min